{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:59:25Z","timestamp":1792519165514,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejps.2013.12.001","type":"journal-article","created":{"date-parts":[[2013,12,9]],"date-time":"2013-12-09T22:46:04Z","timestamp":1386629164000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase"],"prefix":"10.1016","volume":"53","author":[{"given":"Martin","family":"Kr\u00e1tk\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmila","family":"Vin\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Novotn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159ina","family":"Stola\u0159\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2013.12.001_b0005","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1016\/j.tet.2010.05.033","article-title":"Anti-Tuberculosis natural products: synthesis and biological evaluation of pyridoacridine alkaloids related to ascididemin","volume":"66","author":"Appleton","year":"2010","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejps.2013.12.001_b0010","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1021\/jm950538t","article-title":"Quantitative structure\u2013activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters","volume":"39","author":"Bergmann","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0015","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1128\/JB.184.8.2167-2172.2002","article-title":"Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I","volume":"184","author":"Boshoff","year":"2002","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejps.2013.12.001_b0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis","volume":"59","author":"Byrne","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1183\/09031936.00094708","article-title":"Extensively drug-resistant tuberculosis: is its definition correct?","volume":"32","author":"Caminero","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejps.2013.12.001_b0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejps.2013.12.001_b0035","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1016\/j.bmc.2010.10.036","article-title":"High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase","volume":"18","author":"Cheng","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/bmb\/ldq035","article-title":"Nontuberculous mycobacteria: opportunistic environmental pathogens for predisposed hosts","volume":"96","author":"Cook","year":"2010","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ejps.2013.12.001_b0050","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1021\/jm00085a007","article-title":"Antimycobacterial activity of a series of pyrazinoic acid esters","volume":"35","author":"Cynamon","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0045","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1021\/jm00020a003","article-title":"Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity","volume":"38","author":"Cynamon","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/ml200157f","article-title":"Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis","volume":"2","author":"de Carvalho","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2013.12.001_b0060","first-page":"P3","article-title":"Assay methods for key enzymes of the glyoxylate cycle","volume":"72","author":"Dixon","year":"1959","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejps.2013.12.001_b0065","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1021\/jm200305q","article-title":"Current status and research strategies in tuberculosis drug development","volume":"54","author":"Dover","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1590\/S0074-02762006000700001","article-title":"The resumption of consumption. A review on tuberculosis","volume":"101","author":"Ducati","year":"2006","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ejps.2013.12.001_b0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.bmc.2009.12.055","article-title":"Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains","volume":"18","author":"F\u00e9rriz","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0080","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1021\/jm3007596","article-title":"Salicylanilide inhibitors of Toxoplasma gondii","volume":"55","author":"Fomovska","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0085","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1021\/jm200364n","article-title":"Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus","volume":"54","author":"Garner","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0090","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2174\/156802611797183230","article-title":"Prodrugs \u2013 an efficient way to breach delivery and targeting barriers","volume":"11","author":"Huttunen","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0095","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.00110-08","article-title":"Pyrazinamide resistance and pncA Gene Mutations in Mycobacterium tuberculosis","volume":"52","author":"Jureen","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0100","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.2174\/138161211798194521","article-title":"Salicylanilide ester prodrugs as potential antimicrobial agents \u2013 a review","volume":"17","author":"Kr\u00e1tk\u00fd","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejps.2013.12.001_b0105","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.2174\/092986712804485782","article-title":"Advances in mycobacterial isocitrate lyase targeting and inhibitors","volume":"19","author":"Kr\u00e1tk\u00fd","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0115","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1016\/j.ejmech.2010.09.040","article-title":"New amino acid esters of salicylanilides active against MDR-TB and other microbes","volume":"45","author":"Kr\u00e1tk\u00fd","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0110","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2174\/157340612801216346","article-title":"In vitro antibacterial and antifungal activity ofsalicylanilide pyrazine-2-carboxylates","volume":"8","author":"Kr\u00e1tk\u00fd","year":"2012","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0125","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tube.2012.06.001","article-title":"Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase","volume":"92","author":"Kr\u00e1tk\u00fd","year":"2012","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejps.2013.12.001_b0130","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/molecules17010492","article-title":"Antimycobacterial activity of salicylanilide benzenesulfonates","volume":"17","author":"Kr\u00e1tk\u00fd","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2013.12.001_b0135","doi-asserted-by":"crossref","first-page":"12812","DOI":"10.3390\/molecules171112812","article-title":"Antimycobacterial assessment of salicylanilide benzoates including multidrug-resistant tuberculosis strains","volume":"17","author":"Kr\u00e1tk\u00fd","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2013.12.001_b0120","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.3390\/molecules18043674","article-title":"Antibacterial activity of salicylanilide 4-(trifluoromethyl)benzoates","volume":"18","author":"Kr\u00e1tk\u00fd","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2013.12.001_b0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bmc.2012.10.056","article-title":"Structure\u2013activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling","volume":"21","author":"Lee","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update","volume":"15","author":"Lobue","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.ejps.2013.12.001_b0150","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1128\/AAC.00507-11","article-title":"Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tube.2010.03.005","article-title":"The near future: improving the activity of rifamycins and pyrazinamide","volume":"90","author":"Mitchison","year":"2010","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejps.2013.12.001_b0160","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm1252","article-title":"Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence","volume":"11","author":"Mu\u00f1oz-El\u00edas","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejps.2013.12.001_b0165","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1128\/AAC.01458-06","article-title":"Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs","volume":"51","author":"Ngo","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3184\/030823407X200001","article-title":"Synthesis and in vitro activity towards Mycobacterium tuberculosis of l-serinyl ester and amino derivatives of pyrazinoic acid","volume":"3","author":"Pinheiro","year":"2007","journal-title":"J. Chem. Res."},{"key":"10.1016\/j.ejps.2013.12.001_b0175","doi-asserted-by":"crossref","first-page":"11945","DOI":"10.1073\/pnas.0711697105","article-title":"The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejps.2013.12.001_b0180","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1099\/13500872-145-6-1359","article-title":"Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity","volume":"145","author":"Raynaud","year":"1999","journal-title":"Microbiology"},{"key":"10.1016\/j.ejps.2013.12.001_b0190","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1016\/j.bmcl.2011.06.055","article-title":"Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I","volume":"21","author":"Sayahi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2013.12.001_b0185","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1002\/cbdv.201200291","article-title":"Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I","volume":"9","author":"Sayahi","year":"2012","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejps.2013.12.001_b0195","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1021\/jm020310n","article-title":"Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives","volume":"45","author":"Seitz","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0200","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejps.2013.12.001_b0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejps.2009.02.012","article-title":"Lipophilic pyrazinoic acid amide and ester prodrugs. Stability, activation and activity against M. tuberculosis","volume":"37","author":"Sim\u0151es","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.12.001_b0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tube.2003.08.019","article-title":"TB drug discovery: addressing issues of persistence and resistance","volume":"84","author":"Smith","year":"2004","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejps.2013.12.001_b0215","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/AAC.39.6.1269","article-title":"Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide","volume":"39","author":"Speirs","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0220","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/AAC.43.3.537","article-title":"Reduced pyrazinamidase activity and the natural resistance ofMycobacterium kansasii to the antituberculosis drug pyrazinamide","volume":"43","author":"Sun","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0225","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dkl358","article-title":"Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro","volume":"58","author":"Wade","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0230","unstructured":"WHO, 2010. Treatment of tuberculosis Guidelines Fourth edition [online]. [cited 30-10-2012]. <http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241547833_eng.pdf>."},{"key":"10.1016\/j.ejps.2013.12.001_b0235","unstructured":"WHO, 2011. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update [online]. [cited 29-10-2012]. <http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241501583_eng.pdf>."},{"key":"10.1016\/j.ejps.2013.12.001_b0240","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/AAC.39.9.2088","article-title":"In Vitro antimycobacterial activities of pyrazinamide analogs","volume":"39","author":"Yamamoto","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0250","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.ejps.2013.12.001_b0260","first-page":"1320","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis","volume":"13","author":"Zhang","year":"2009","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.ejps.2013.12.001_b0255","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0265","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jac\/dkg287","article-title":"Susceptibility of Mycobacterium tuberculosis to weak acids","volume":"52","author":"Zhang","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0245","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1742-4658.2007.06241.x","article-title":"Characterization of Mycobacterium tuberculosis nicotinamidase\/pyrazinamidase","volume":"275","author":"Zhang","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.ejps.2013.12.001_b0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/14756361003671060","article-title":"Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase","volume":"26","author":"Zhu","year":"2011","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejps.2013.12.001_b0275","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.01369-06","article-title":"Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli","volume":"51","author":"Zimhony","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2013.12.001_b0280","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tube.2011.09.002","article-title":"Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance","volume":"92","author":"Zimic","year":"2012","journal-title":"Tuberculosis"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713004582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713004582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T14:44:47Z","timestamp":1564929887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098713004582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":56,"alternative-id":["S0928098713004582"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2013.12.001","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}